Prescription medicine
Fluoroestradiol f 18 Brand names: Cerianna
Fluoroestradiol f 18 (Cerianna) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the fluoroestradiol f 18 FDA label on DailyMed (effective January 12, 2026, GE Healthcare Inc.); the NDA 212155 record on Drugs@FDA; every fluoroestradiol f 18 label on DailyMed.
Highlights of the record
FDA label of January 12, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageCERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Forms and strengths
Injection.
On the market
- Earliest approval on file
- May 20, 2020 Cerianna, Ge Healthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 19 through July 30, 2026
What is fluoroestradiol f 18 used for?
From the label: indications and usageCERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. ( 1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. […]
FDA pharmacologic class: Radioactive Diagnostic Agent.
Source: FDA drug label (CERIANNA), GE Healthcare Inc., effective January 12, 2026 (SPL set b2c2a2df-cf3e-4a29-a033-231ed5a94b58), via openFDA; the full label on DailyMed
Is there a generic for fluoroestradiol f 18 (Cerianna)?
No generic fluoroestradiol f 18 is approved (Drugs@FDA, October 8, 2026).
- 2020 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the fluoroestradiol f 18 label say about other medicines?
The fluoroestradiol f 18 label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Elacestrant | drug interactions | Before administering CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives (e.g., elacestrant for 11 days, tamoxifen for 8 weeks, and fulvestrant for 28 weeks) [see Dosage and Administration (2.3) ]. |
| Fulvestrant | drug interactions | Before administering CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives (e.g., elacestrant for 11 days, tamoxifen for 8 weeks, and fulvestrant for 28 weeks) [see Dosage and Administration (2.3) ]. |
| Tamoxifen | drug interactions | Before administering CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives (e.g., elacestrant for 11 days, tamoxifen for 8 weeks, and fulvestrant for 28 weeks) [see Dosage and Administration (2.3) ]. |
Source: FDA drug label (CERIANNA), GE Healthcare Inc., effective January 12, 2026 (SPL set b2c2a2df-cf3e-4a29-a033-231ed5a94b58), via openFDA; the full label on DailyMed
What do FAERS reports show for fluoroestradiol f 18?
The FDA Adverse Event Reporting System holds 19 reports that list fluoroestradiol f 18 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 1 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radioactive diagnostic agents
- the pharmacologic class, with prices and generics
- Fluoroestradiol f 18 side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other